S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SRPT Sarepta Therapeutics Inc New

105.35

0.00 (0.00%)

Pre Market

Last Updated: 06:28:07

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics Inc New News

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
Friday 14 February 2025 (5 days ago) • Edgar (US Regulatory)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 14 February 2025 (5 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 14 February 2025 (5 days ago) • Edgar (US Regulatory)

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
Friday 14 February 2025 (5 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 13 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 13 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 13 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 13 February 2025 (6 days ago) • Edgar (US Regulatory)

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
Wednesday 12 February 2025 (7 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Friday 31 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
Monday 27 January 2025 (3 weeks ago) • Business Wire

Form 8-K - Current report
Monday 13 January 2025 (1 month ago) • Edgar (US Regulatory)

More Sarepta Therapeutics Inc New News Articles

Digital Brand Media and ... (PK)

TheGlobe com (PK)

Clean Vision (QB)

Asia Broadband (PK)

Intergrated Cannabis Sol... (PK)

Super Micro Computer

Voip Pal Com (QB)

Rennova Health (CE)

Green Leaf Innovations (PK)

Valiant Eagle (PK)

Cann American (CE)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions